- Home
- ATHA
ATHA
Athira Pharma Inc.
as 11-15-2024 4:00pm EST
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 93.5M | IPO Year: | 2020 |
| Target Price: | $11.25 | AVG Volume (30 days): | 14.2M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.41 - $4.30 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Athira Pharma Inc. (ATHA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Litton Mark James | ATHA | President and CEO | Sep 3 '24 | Sell | $0.57 | 5,032 | $2,848.11 | 159,365 | |
| Gengos Andrew | ATHA | CFO and Chief Business Officer | Sep 3 '24 | Sell | $0.57 | 1,272 | $719.95 | 97,532 | |
| Lenington Rachel | ATHA | COO and CDO | Sep 3 '24 | Sell | $0.57 | 2,525 | $1,429.15 | 20,870 | |
| Worthington Mark | ATHA | GENERAL COUNSEL | Sep 3 '24 | Sell | $0.57 | 2,525 | $1,429.15 | 51,927 | |
| CHURCH KEVIN | ATHA | CHIEF SCIENTIFIC OFFICER | Sep 3 '24 | Sell | $0.57 | 2,525 | $1,429.15 | 92,684 |
Latest Athira Pharma Inc. News
ATHA Breaking Stock News: Dive into ATHA Ticker-Specific Updates for Smart Investing
BioPharma Dive
10 days ago
Athira exploring strategic alternatives after Alzheimer’s failure
GlobeNewswire
10 days ago
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Simply Wall St.
13 days ago
US Penny Stocks: November 2024's Top Picks To Consider
GlobeNewswire
a month ago
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
GlobeNewswire
2 months ago
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Zacks
2 months ago
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
MT Newswires
2 months ago
Top Midday Decliners
MT Newswires
2 months ago
Sector Update: Health Care Stocks Retreat Wednesday Afternoon
Compare ATHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATHA Athira Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.